CNS Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $3 | $3 |
Gross Profit | -1 | -1 | ||
EBITDA | -3,215 | -2,369 | -4,294 | -3,172 |
EBIT | -3,216 | -2,370 | -4,295 | -3,173 |
Net Income | -3,218 | -2,374 | -4,301 | -3,176 |
Net Change In Cash | 0 | 0 | 3 | 3 |
Free Cash Flow | -2,174 | -5,343 | -3,241 | -5,475 |
Cash | 9,864 | 12,129 | 13,047 | 6,461 |
Basic Shares | 30 | 30 | 226 | 1,841 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -3 | -4 | -11 | -13 |
EBITDA | -14,838 | -18,860 | -15,255 | -14,472 |
EBIT | -14,841 | -18,865 | -15,267 | -14,485 |
Net Income | -14,857 | -18,851 | -15,274 | -14,495 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -17,117 | -14,143 | -10,562 | -13,544 |
Cash | 6,461 | 548 | 10,055 | 5,004 |
Basic Shares | 317 | 6,225 | 2,260 | 1,458 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | -$5.76 |
2025-06-30 | -$6.42 |
2025-03-31 | -$2.24 |
2024-12-31 | -$37.33 |
